RAF1 and thyroid gland carcinoma: These data, along with the logic of targeting RAF, RET and VEGF in thyroid cancer therapy led to the development of several phase 2 studies of Sorafenib as a solitary agent for treatment-refractory differentiated or anaplastic thyroid cancer that are ongoing or were recently completed.